Nuance Investments LLC decreased its stake in shares of Envista Holdings Co. (NYSE:NVST - Free Report) by 34.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 4,802,214 shares of the company's stock after selling 2,544,320 shares during the quarter. Envista comprises about 3.7% of Nuance Investments LLC's portfolio, making the stock its 8th largest holding. Nuance Investments LLC owned approximately 2.79% of Envista worth $92,635,000 as of its most recent filing with the SEC.
Several other institutional investors also recently bought and sold shares of NVST. Cerity Partners LLC boosted its holdings in shares of Envista by 40.1% during the 3rd quarter. Cerity Partners LLC now owns 37,995 shares of the company's stock valued at $751,000 after purchasing an additional 10,883 shares during the last quarter. Daiwa Securities Group Inc. grew its position in Envista by 24.8% in the third quarter. Daiwa Securities Group Inc. now owns 53,332 shares of the company's stock worth $1,054,000 after acquiring an additional 10,600 shares in the last quarter. Qsemble Capital Management LP bought a new stake in Envista during the third quarter worth approximately $397,000. Glenmede Trust Co. NA purchased a new stake in Envista during the third quarter valued at approximately $217,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in shares of Envista by 0.8% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 425,502 shares of the company's stock valued at $8,408,000 after purchasing an additional 3,199 shares during the last quarter.
Envista Stock Down 5.9 %
NYSE:NVST traded down $1.07 during trading hours on Friday, reaching $16.96. The company's stock had a trading volume of 6,605,419 shares, compared to its average volume of 2,421,373. The stock has a 50 day moving average price of $19.59 and a two-hundred day moving average price of $19.60. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.76 and a current ratio of 2.04. The company has a market capitalization of $2.92 billion, a P/E ratio of -2.61, a price-to-earnings-growth ratio of 1.27 and a beta of 1.33. Envista Holdings Co. has a 12 month low of $15.15 and a 12 month high of $23.00.
Envista (NYSE:NVST - Get Free Report) last issued its quarterly earnings data on Wednesday, February 5th. The company reported $0.24 earnings per share for the quarter, beating analysts' consensus estimates of $0.23 by $0.01. Envista had a positive return on equity of 3.86% and a negative net margin of 44.56%. Equities analysts predict that Envista Holdings Co. will post 1 EPS for the current fiscal year.
Wall Street Analyst Weigh In
Several analysts recently weighed in on NVST shares. UBS Group decreased their price target on Envista from $23.00 to $21.00 and set a "neutral" rating on the stock in a report on Monday, March 10th. Wells Fargo & Company set a $19.00 target price on shares of Envista in a research note on Saturday, March 8th. Jefferies Financial Group lifted their price target on shares of Envista from $20.00 to $22.00 and gave the stock a "hold" rating in a research note on Thursday, January 23rd. New Street Research set a $19.00 price objective on shares of Envista in a research report on Thursday, March 6th. Finally, Morgan Stanley decreased their price objective on shares of Envista from $20.00 to $19.00 and set an "equal weight" rating for the company in a research note on Thursday, March 6th. Two investment analysts have rated the stock with a sell rating, ten have assigned a hold rating and three have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $20.18.
Check Out Our Latest Analysis on Envista
Envista Company Profile
(
Free Report)
Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.
Further Reading
Before you consider Envista, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Envista wasn't on the list.
While Envista currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
